Tectonic Therapeutic (TECX) Research & Development (2017 - 2026)

Tectonic Therapeutic (TECX) has reported Research & Development for 10 consecutive years, with $20.9 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Research & Development rose 60.1% year-over-year to $20.9 million; the TTM figure through Mar 2026 stood at $71.3 million (up 63.65% YoY), while the FY2025 annual figure was $63.5 million, up 53.49% from the prior year.
• Research & Development rose to $20.9 million in Q1 2026 per TECX's latest filing, from $16.3 million in the prior quarter.
• Across five years, Research & Development topped out at $20.9 million in Q1 2026 and bottomed at $7.1 million in Q2 2024.
• Historically, Research & Development has averaged $14.1 million across 5 years, with a median of $15.9 million in 2022.
• Annual changes were most pronounced in 2023 — Research & Development tumbled 60.35% — and 2025, when it jumped 142.93%.
• Tectonic Therapeutic's Research & Development stood at $18.1 million in 2022, then sank by 60.35% to $7.2 million in 2023, then gained by 27.31% to $9.2 million in 2024, then surged by 78.47% to $16.3 million in 2025, then advanced by 27.72% to $20.9 million in 2026.
• Business Quant data shows TECX's Research & Development at $20.9 million in Q1 2026, $16.3 million in Q4 2025, and $16.9 million in Q3 2025.